H2Biologics gets exclusive rights for human granzyme B (GrB) to develop immunoconjugate with a human single domain antibody (SD1) that targets mesothelin-expressing tumors.
Shrewsbury, Mass. - H2Biologics announced that it has been granted a worldwide, exclusive license by the Research Development Foundation (RDF) for the ...
Satisfied Users & 
Approved Press Releases
